Download in electronic PDF format for $75

Abstract:  A postmenopausal female patient was suffering from vulvovaginal symptoms such as dryness and irritation, which were affecting her relationship with her partner and her overall quality of life. The patient was instructed to apply an estriol 0.1% vaginal ointment (PCCA Ellage Anhydrous Vaginal) for a duration of three months. The safety and efficacy of the compounded treatment were evaluated using an online data collection form, which included the validated Vulvovaginal Symptom Questionnaire. Post-treatment results show that the vulvovaginal symptoms were no longer bothersome, and that the patient’s relationship was no longer affected. There were no reports of undesirable effects as a result of the compounded treatment. This case study reinforces the benefits and convenience of using topical hormone replacement therapy in postmenopausal women.

Related Keywords: Ramona Lima, RPh, FAARFM, ABAAHP, Mark A. Gonzalez, PharmD, Craig Urwin, BSc (Hons), Linda Jean, BPharm, ARPharmS, Maria Carvalho, PharmD, MRPharmS, PhD, Fabiana Banov, RPh, MS, vulvovaginal symptoms, vulvar irritation, vaginal dryness, postmenopausal women, menopause, estrogen deficiency, chronic vaginal atrophy, dyspareunia, painful intercourse, sexual function, quality of life, relationships, estriol 0.1% vaginal ointment, topical preparation, topical hormone replacement therapy, intravaginal administration, Vulvovaginal Symptom Questionnaire, drug safety, formulations

Related Categories: FORMULATIONS, HRT, MENTAL HEALTH, CASE REPORTS, DOSAGE FORMS/DRUG CARRIERS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version